The drug executive President Donald Trump has picked to lead the Department Health and Human Servicesisn’t likely to shy away from the topic of sky-high medication prices -- but it may beinsurers and drug plans that feel the heat as much as his former industry.

Trump’s pick, former Eli Lilly & Co. executive Alex Azar hastalked about drug prices during interviews, speeches and panelappearances before leaving Lilly in January and in the monthsafter. His remarks have paralleled a common industry argument, thatit’s other parts of the pharmaceutical supply chain that bear alarge share of the blame for U.S. outrage over drug costs.

“Why did things erupt? They erupted because we have seen acomplete and fundamental restructuring of health insurance in theUnited States over the last three to five years,” Azar said at a conference in Mayhosted by a medical software company.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.